Retrieve available abstracts of 70 articles: HTML format
Single Articles
December 2025
KEDHI E, Hermanides RS, Dambrink JE, Singh SK, et al TransCatheter aortic valve implantation and fractional flow reserve-guided
percutaneous coronary intervention versus conventional surgical aortic valve
replacement and coronary bypass grafting for treatment of patients with aortic
valve stenosis and c
Lancet. 2025;404:2593-2602. PubMedAbstract available
TARANTINI G, Cardaioli F TAVI and PCI: redefining treatment for aortic stenosis and complex coronary
artery disease.
Lancet. 2025;404:2492-2493. PubMed
June 2025
CONRAD N, Rahimi K, McMurray JJV, Casadei B, et al The changing spectrum of cardiovascular diseases.
Lancet. 2025 Jun 9:S0140-6736(25)00990-0. doi: 10.1016/S0140-6736(25)00990. PubMed
THE LANCET From innovation to impact in cardiovascular disease.
Lancet. 2025;405:2023. PubMed
May 2025
LEE SJ, Kim BK Obicetrapib-ezetimibe combination therapy for patients with atherosclerotic
cardiovascular disease.
Lancet. 2025 May 5:S0140-6736(25)00827-X. doi: 10.1016/S0140-6736(25)00827. PubMed
April 2025
HUANG C Ticagrelor monotherapy for acute coronary syndromes.
Lancet. 2025;405:1463. PubMed
VALGIMIGLI M, Hong SJ, Gragnano F, Hong MK, et al Ticagrelor monotherapy for acute coronary syndromes - Authors' reply.
Lancet. 2025;405:1463-1464. PubMed
APOSTOLOS A, Tsigkas G Ticagrelor monotherapy for acute coronary syndromes.
Lancet. 2025;405:1462-1463. PubMed
GUO C, Shan D, Liu Z, He F, et al Ticagrelor monotherapy for acute coronary syndromes.
Lancet. 2025;405:1461-1462. PubMed
CHOI KH, Park YH, Lee JY, Jeong JO, et al Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high
risk of subsequent cardiovascular event after percutaneous coronary intervention
(SMART-CHOICE 3): a randomised, open-label, multicentre trial.
Lancet. 2025 Mar 28:S0140-6736(25)00449-0. doi: 10.1016/S0140-6736(25)00449. PubMedAbstract available
FEARON WF, Zimmermann FM, Ding VY, Takahashi K, et al Outcomes after fractional flow reserve-guided percutaneous coronary intervention
versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a
multicentre, open-label, randomised trial.
Lancet. 2025 Mar 28:S0140-6736(25)00505-7. doi: 10.1016/S0140-6736(25)00505. PubMedAbstract available
HU X, Zhang J, Yang S, Jiang J, et al Angiography-derived fractional flow reserve versus intravascular ultrasound to
guide percutaneous coronary intervention in patients with coronary artery disease
(FLAVOUR II): a multicentre, randomised, non-inferiority trial.
Lancet. 2025 Mar 28:S0140-6736(25)00504-5. doi: 10.1016/S0140-6736(25)00504. PubMedAbstract available
KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al Orbital atherectomy versus balloon angioplasty before drug-eluting stent
implantation in severely calcified lesions eligible for both treatment strategies
(ECLIPSE): a multicentre, open-label, randomised trial.
Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450. PubMedAbstract available
TAM DY, Lee G, Chikwe J Fractional flow reserve-guided percutaneous coronary intervention versus coronary
artery bypass grafting: please mind the gap.
Lancet. 2025 Mar 28:S0140-6736(25)00583-5. doi: 10.1016/S0140-6736(25)00583. PubMed
COUGHLAN JJ, Byrne RA Orbital atherectomy for severely calcified coronary artery lesions.
Lancet. 2025 Mar 28:S0140-6736(25)00572-0. doi: 10.1016/S0140-6736(25)00572. PubMed
ROSSELLO X, Kristensen AMD Clopidogrel use in chronic coronary syndrome: a fragile lifelong choice.
Lancet. 2025 Mar 28:S0140-6736(25)00562-8. doi: 10.1016/S0140-6736(25)00562. PubMed
ZAMAN S, Wasfy JH, Kapil V, Ziaeian B, et al The Lancet Commission on rethinking coronary artery disease: moving from
ischaemia to atheroma.
Lancet. 2025 Mar 25:S0140-6736(25)00055-8. doi: 10.1016/S0140-6736(25)00055. PubMed
THE LANCET Rethinking coronary artery disease: a call to action.
Lancet. 2025 Mar 25:S0140-6736(25)00497-0. doi: 10.1016/S0140-6736(25)00497. PubMed
CHANDRASHEKHAR Y, Mensah G, Narula J From coronary artery disease to atherosclerotic coronary artery disease: what is
in a name?
Lancet. 2025 Mar 25:S0140-6736(25)00563-X. doi: 10.1016/S0140-6736(25)00563. PubMed
WILSON C Nancy Brown: using advocacy to advance cardiovascular health.
Lancet. 2025;405:688. PubMed
February 2025
XU C Inflammatory cardiovascular events and coronary artery disease.
Lancet. 2025;405:545. PubMed
CHAN K, Neubauer S, Channon KM, Deanfield J, et al Inflammatory cardiovascular events and coronary artery disease - Authors' reply.
Lancet. 2025;405:545-546. PubMed
ZHAO K, Chen L, Sun Z Inflammatory cardiovascular events and coronary artery disease.
Lancet. 2025;405:544. PubMed
NURMOHAMED NS, Beverloo CYY, Kraaijenhof JM, Stroes ESG, et al Inflammatory cardiovascular events and coronary artery disease.
Lancet. 2025;405:544-545. PubMed
January 2025
WILLIAMS MC, Wereski R, Tuck C, Adamson PD, et al Coronary CT angiography-guided management of patients with stable chest pain:
10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
Lancet. 2025;405:329-337. PubMedAbstract available
November 2024
LUSEBRINK E, Binzenhofer L, Adamo M, Lorusso R, et al Cardiogenic shock.
Lancet. 2024;404:2006-2020. PubMedAbstract available
October 2024
ANDERSEN BK, Sejr-Hansen M, Maillard L, Campo G, et al Quantitative flow ratio versus fractional flow reserve for coronary
revascularisation guidance (FAVOR III Europe): a multicentre, randomised,
non-inferiority trial.
Lancet. 2024 Oct 29:S0140-6736(24)02175-5. doi: 10.1016/S0140-6736(24)02175. PubMedAbstract available
BECKER LM, Swaans MJ Present and future of functional measurements in coronary revascularisation.
Lancet. 2024 Oct 29:S0140-6736(24)02367-5. doi: 10.1016/S0140-6736(24)02367. PubMed
ERLINGE D, Andersson J, Frobert O, Tornerud M, et al Bioadaptor implant versus contemporary drug-eluting stent in percutaneous
coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind,
non-inferiority, registry-based, randomised controlled trial.
Lancet. 2024 Oct 25:S0140-6736(24)02227-X. doi: 10.1016/S0140-6736(24)02227. PubMedAbstract available
CAPODANNO D Coronary stenting with bioadaptors.
Lancet. 2024 Oct 25:S0140-6736(24)02359-6. doi: 10.1016/S0140-6736(24)02359. PubMed
September 2024
THIELE H, Moller JE, Henriques JPS, Bogerd M, et al Temporary mechanical circulatory support in infarct-related cardiogenic shock: an
individual patient data meta-analysis of randomised trials with 6-month
follow-up.
Lancet. 2024;404:1019-1028. PubMedAbstract available
NORDESTGAARD BG, Langsted A Lipoprotein(a) and cardiovascular disease.
Lancet. 2024 Sep 12:S0140-6736(24)01308-4. doi: 10.1016/S0140-6736(24)01308. PubMedAbstract available
August 2024
KRUMHOLZ HM, Geraldes F, Wilson C, Horton R, et al The Lancet-JACC collaboration: advancing cardiovascular health.
Lancet. 2024;404:833-834. PubMed
JENTZER JC, Hibbert B Optimal patient and mechanical circulatory support device selection in acute
myocardial infarction cardiogenic shock.
Lancet. 2024 Aug 30:S0140-6736(24)01588-5. doi: 10.1016/S0140-6736(24)01588. PubMed
HONG SJ, Lee SJ, Lee SH, Lee JY, et al Optical coherence tomography-guided versus angiography-guided percutaneous
coronary intervention for patients with complex lesions (OCCUPI): an
investigator-initiated, multicentre, randomised, open-label, superiority trial in
South Korea.
Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454. PubMedAbstract available
MAMAS MA, Mintz GS Optical coherence tomography imaging for complex percutaneous coronary
intervention.
Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593. PubMed
GAO C, He X, Ouyang F, Zhang Z, et al Drug-coated balloon angioplasty with rescue stenting versus intended stenting for
the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I):
an open-label, randomised, non-inferiority trial.
Lancet. 2024 Aug 30:S0140-6736(24)01594-0. doi: 10.1016/S0140-6736(24)01594. PubMedAbstract available
MCENTEGART MB, Kirtane AJ How feasible is a cage-free solution for de novo coronary artery disease?
Lancet. 2024 Aug 30:S0140-6736(24)01696-9. doi: 10.1016/S0140-6736(24)01696. PubMed
VALGIMIGLI M, Hong SJ, Gragnano F, Chalkou K, et al De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet
therapy in patients with and without acute coronary syndromes: a systematic
review and individual patient-level meta-analysis of randomised trials.
Lancet. 2024 Aug 30:S0140-6736(24)01616-7. doi: 10.1016/S0140-6736(24)01616. PubMedAbstract available
STEFANINI GG, Oliva A Is this the conclusive evidence for ticagrelor monotherapy in acute coronary
syndromes?
Lancet. 2024 Aug 30:S0140-6736(24)01678-7. doi: 10.1016/S0140-6736(24)01678. PubMed
DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al Semaglutide and cardiovascular outcomes in patients with obesity and prevalent
heart failure: a prespecified analysis of the SELECT trial.
Lancet. 2024;404:773-786. PubMedAbstract available
June 2024
LIU J, Li Y, Ge J, Yan X, et al Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm
Hg in patients with high cardiovascular risk with and without diabetes or
previous stroke: an open-label, blinded-outcome, randomised trial.
Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028. PubMedAbstract available
GAO Y, Li Z, Liu M, Tian J, et al VA-ECMO for infarct-related cardiogenic shock.
Lancet. 2024;403:2487. PubMed
YU Z, Li G VA-ECMO for infarct-related cardiogenic shock.
Lancet. 2024;403:2487. PubMed
ZEYMER U, Freund A, Hochadel M, Schneider S, et al VA-ECMO for infarct-related cardiogenic shock - Authors' reply.
Lancet. 2024;403:2487-2488. PubMed
LI Y VA-ECMO for infarct-related cardiogenic shock.
Lancet. 2024;403:2486. PubMed
DALZELL JR VA-ECMO for infarct-related cardiogenic shock.
Lancet. 2024;403:2486. PubMed
WANG G, Guan J, Liu Z VA-ECMO for infarct-related cardiogenic shock.
Lancet. 2024;403:2485. PubMed
KELLY P, Lemmens R, Weimar C, Walsh C, et al Long-term colchicine for the prevention of vascular recurrent events in
non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
Lancet. 2024 Jun 7:S0140-6736(24)00968-1. doi: 10.1016/S0140-6736(24)00968. PubMedAbstract available
May 2024
CHAN K, Wahome E, Tsiachristas A, Antonopoulos AS, et al Inflammatory risk and cardiovascular events in patients without obstructive
coronary artery disease: the ORFAN multicentre, longitudinal cohort study.
Lancet. 2024 May 29:S0140-6736(24)00596-8. doi: 10.1016/S0140-6736(24)00596. PubMedAbstract available
COUTTS SB, Ankolekar S, Appireddy R, Arenillas JF, et al Tenecteplase versus standard of care for minor ischaemic stroke with proven
occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921. PubMedAbstract available
April 2024
FOLEY MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, et al Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a
randomised, placebo-controlled trial.
Lancet. 2024;403:1543-1553. PubMedAbstract available
MONTI CB, Palmisano A Coronary sinus reducer: a new hope for refractory angina?
Lancet. 2024;403:1514-1515. PubMed
LI X, Ge Z, Kan J, Anjum M, et al Intravascular ultrasound-guided versus angiography-guided percutaneous coronary
intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre,
randomised trial.
Lancet. 2024 Apr 5:S0140-6736(24)00282-4. doi: 10.1016/S0140-6736(24)00282. PubMedAbstract available
DEN DEKKER WK Is intravascular imaging the future of percutaneous coronary intervention?
Lancet. 2024 Apr 5:S0140-6736(24)00430-6. doi: 10.1016/S0140-6736(24)00430. PubMed
GE Z, Kan J, Gao X, Raza A, et al Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after
percutaneous coronary intervention in patients with acute coronary syndromes
(ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
Lancet. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473. PubMedAbstract available
STEINER-GAGER GM, Siller-Matula JM Abbreviated dual antiplatelet therapy after acute coronary syndrome.
Lancet. 2024 Apr 5:S0140-6736(24)00586-5. doi: 10.1016/S0140-6736(24)00586. PubMed
PARK SJ, Ahn JM, Kang DY, Yun SC, et al Preventive percutaneous coronary intervention versus optimal medical therapy
alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT):
a multicentre, open-label, randomised controlled trial.
Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413. PubMedAbstract available
BOROVAC JA Percutaneous coronary intervention for non-obstructive vulnerable plaques.
Lancet. 2024 Apr 4:S0140-6736(24)00488-4. doi: 10.1016/S0140-6736(24)00488. PubMed
March 2024
RIDKER PM, Bhatt DL, Nissen SE Inflammation, infection, and cardiovascular risk - Authors' reply.
Lancet. 2024;403:1025-1026. PubMed
SHARMA S, Sharma R Inflammation, infection, and cardiovascular risk.
Lancet. 2024;403:1024-1025. PubMed
GOLDMAN M, Bondue A, Cogan E Inflammation, infection, and cardiovascular risk.
Lancet. 2024;403:1023. PubMed
GOLDSTEIN MR, Mascitelli L Inflammation, infection, and cardiovascular risk.
Lancet. 2024;403:1023-1024. PubMed
DROZD M, Cubbon R Inflammation, infection, and cardiovascular risk.
Lancet. 2024;403:1022-1023. PubMed
PAREEK A, Chandurkar N, Naidu K, Raut V, et al Inflammation, infection, and cardiovascular risk.
Lancet. 2024;403:1022. PubMed
STRANDBERG TE, Kovanen PT, Gylling H Inflammation, infection, and cardiovascular risk.
Lancet. 2024;403:1021. PubMed
LIN GM, Huang WC, Han CL Inflammation, infection, and cardiovascular risk.
Lancet. 2024;403:1021-1022. PubMed
February 2024
LEE ZS, Ryan N Intravascular imaging in percutaneous coronary intervention.
Lancet. 2024 Feb 21:S0140-6736(23)02686-7. doi: 10.1016/S0140-6736(23)02686. PubMed
STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al Intravascular imaging-guided coronary drug-eluting stent implantation: an updated
network meta-analysis.
Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454. PubMedAbstract available